DK2834233T3 - NEW ALPHA2 ADRENOCEPTOR AGONISTS - Google Patents
NEW ALPHA2 ADRENOCEPTOR AGONISTS Download PDFInfo
- Publication number
- DK2834233T3 DK2834233T3 DK13719297.7T DK13719297T DK2834233T3 DK 2834233 T3 DK2834233 T3 DK 2834233T3 DK 13719297 T DK13719297 T DK 13719297T DK 2834233 T3 DK2834233 T3 DK 2834233T3
- Authority
- DK
- Denmark
- Prior art keywords
- dihydro
- imidazole
- methylisochroman
- alkyl
- hydrochloride
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261619109P | 2012-04-02 | 2012-04-02 | |
| PCT/FI2013/000013 WO2013150173A1 (en) | 2012-04-02 | 2013-03-28 | New alpha2 adrenoceptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2834233T3 true DK2834233T3 (en) | 2018-06-18 |
Family
ID=48224812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13719297.7T DK2834233T3 (en) | 2012-04-02 | 2013-03-28 | NEW ALPHA2 ADRENOCEPTOR AGONISTS |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9249127B2 (ja) |
| EP (1) | EP2834233B1 (ja) |
| JP (1) | JP6427096B2 (ja) |
| KR (1) | KR102104228B1 (ja) |
| CN (1) | CN104220437B (ja) |
| AR (1) | AR090557A1 (ja) |
| AU (1) | AU2013244859B2 (ja) |
| BR (1) | BR112014023957B1 (ja) |
| CA (1) | CA2868611C (ja) |
| DK (1) | DK2834233T3 (ja) |
| ES (1) | ES2674945T3 (ja) |
| FR (1) | FR22C1005I1 (ja) |
| HK (1) | HK1205115A1 (ja) |
| HR (1) | HRP20181203T1 (ja) |
| HU (2) | HUE039290T2 (ja) |
| IL (1) | IL234663B (ja) |
| LT (2) | LT2834233T (ja) |
| MX (1) | MX358429B (ja) |
| NL (1) | NL301160I2 (ja) |
| NO (1) | NO2022002I1 (ja) |
| PL (1) | PL2834233T3 (ja) |
| PT (1) | PT2834233T (ja) |
| RU (1) | RU2642065C2 (ja) |
| SI (1) | SI2834233T1 (ja) |
| TW (1) | TWI620746B (ja) |
| WO (1) | WO2013150173A1 (ja) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2015152196A1 (ja) * | 2014-03-31 | 2017-04-13 | 東レ株式会社 | イミダゾリン誘導体及びその医薬用途 |
| US9856238B2 (en) * | 2015-02-11 | 2018-01-02 | Sunovion Pharmaceuticals Inc. | 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders |
| CN105646306B (zh) * | 2015-12-11 | 2020-06-30 | 广东莱佛士制药技术有限公司 | 一种4-甲硫基苯乙酸的制备方法 |
| WO2019106238A1 (en) * | 2017-12-01 | 2019-06-06 | Orion Corporation | Process for the preparation of 2-(5-methoxyisochroman-1 -yl)-4,5-dihydro-1 h-imidazole and the hydrogensulfate salt thereof |
| CN110272407B (zh) * | 2019-07-22 | 2021-02-05 | 河北省农林科学院经济作物研究所 | 一种用于降血压的天然异色满酮类化合物 |
| US20240173254A1 (en) | 2021-03-19 | 2024-05-30 | Orion Corporation | Tasipimidine formulations and use thereof |
| WO2023139313A1 (en) | 2022-01-24 | 2023-07-27 | Orion Corporation | Novel sulfate salt forms of isochroman-imidazole structured alpha-2a adrenoceptor agonist |
| WO2023148431A1 (en) | 2022-02-04 | 2023-08-10 | Orion Corporation | Novel salt forms of isochroman-imidazole structured alpha-2a adrenoceptor agonist |
| WO2024069050A1 (en) | 2022-09-28 | 2024-04-04 | Orion Corporation | Tasipimidine and cyp2d6 inhibitor combination treatment |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1247008B (de) * | 1965-10-05 | 1967-08-10 | Huels Chemische Werke Ag | Thermoplastische Massen zur Herstellung von vergilbungsfreien antielektrostatischen Formkoerpern aus Polyolefinen |
| US3438995A (en) | 1968-01-08 | 1969-04-15 | Melville Sahyun | Diazaheterocyclic substituted benz-oxaheterocyclic compounds |
| EP0166937B1 (en) * | 1984-06-06 | 1991-08-28 | Abbott Laboratories | Adrenergic compounds |
| AU744798B2 (en) * | 1997-12-04 | 2002-03-07 | Allergan, Inc. | Substituted imidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors |
| FI20000073A0 (fi) * | 2000-01-14 | 2000-01-14 | Orion Yhtymae Oy | Uusia imidatsolijohdannaisia |
| WO2007085558A1 (en) | 2006-01-27 | 2007-08-02 | F. Hoffmann-La Roche Ag | Use of 2-imidazoles for the treatment of cns disorders |
| CA2637308C (en) | 2006-01-27 | 2014-02-25 | F. Hoffmann-La Roche Ag | Use of 4-imidazole derivatives for cns disorders |
| US20080020076A1 (en) * | 2006-07-21 | 2008-01-24 | Khem Jhamandas | Methods and Therapies for Potentiating a Therapeutic Action of an Alpha-2 Adrenergic Receptor Agonist and Inhibiting and/or Reversing Tolerance to Alpha-2 Adrenergic Receptor Agonists |
-
2013
- 2013-03-27 AR ARP130101043 patent/AR090557A1/es active IP Right Grant
- 2013-03-28 BR BR112014023957-6A patent/BR112014023957B1/pt active IP Right Grant
- 2013-03-28 LT LTEP13719297.7T patent/LT2834233T/lt unknown
- 2013-03-28 WO PCT/FI2013/000013 patent/WO2013150173A1/en active Application Filing
- 2013-03-28 CN CN201380018776.XA patent/CN104220437B/zh active Active
- 2013-03-28 MX MX2014011851A patent/MX358429B/es active IP Right Grant
- 2013-03-28 EP EP13719297.7A patent/EP2834233B1/en active Active
- 2013-03-28 PT PT137192977T patent/PT2834233T/pt unknown
- 2013-03-28 SI SI201331024T patent/SI2834233T1/en unknown
- 2013-03-28 HU HUE13719297A patent/HUE039290T2/hu unknown
- 2013-03-28 PL PL13719297T patent/PL2834233T3/pl unknown
- 2013-03-28 US US14/389,466 patent/US9249127B2/en active Active
- 2013-03-28 DK DK13719297.7T patent/DK2834233T3/en active
- 2013-03-28 CA CA2868611A patent/CA2868611C/en active Active
- 2013-03-28 AU AU2013244859A patent/AU2013244859B2/en active Active
- 2013-03-28 RU RU2014144284A patent/RU2642065C2/ru active
- 2013-03-28 JP JP2015503903A patent/JP6427096B2/ja active Active
- 2013-03-28 ES ES13719297.7T patent/ES2674945T3/es active Active
- 2013-03-28 KR KR1020147027610A patent/KR102104228B1/ko active IP Right Grant
- 2013-03-29 TW TW102111298A patent/TWI620746B/zh active
-
2014
- 2014-09-15 IL IL234663A patent/IL234663B/en active IP Right Grant
-
2015
- 2015-06-16 HK HK15105661.0A patent/HK1205115A1/xx unknown
-
2018
- 2018-07-25 HR HRP20181203TT patent/HRP20181203T1/hr unknown
-
2022
- 2022-01-27 NO NO2022002C patent/NO2022002I1/no unknown
- 2022-01-31 FR FR22C1005C patent/FR22C1005I1/fr active Active
- 2022-01-31 NL NL301160C patent/NL301160I2/nl unknown
- 2022-02-02 HU HUS2200005C patent/HUS2200005I1/hu unknown
- 2022-02-03 LT LTPA2022001C patent/LTPA2022001I1/lt unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2834233T3 (en) | NEW ALPHA2 ADRENOCEPTOR AGONISTS | |
| AU2016222140B2 (en) | Fused-ring compounds, pharmaceutical composition and uses thereof | |
| EP3464249B1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| KR102491125B1 (ko) | Sumo 활성화 효소의 억제제로서 유용한 헤테로아릴 화합물 | |
| RU2655914C2 (ru) | Соединения дигидропиримидина и их применение в фармацевтических препаратах | |
| EP2921480B1 (en) | Nitrogen-containing heterocyclic compound | |
| KR20220154174A (ko) | Yap/taz-tead 단백질-단백질 상호작용 억제제로서의 바이아릴 유도체 | |
| WO2016022569A1 (en) | Compositions useful for treating disorders related to kit | |
| KR20150041787A (ko) | 2,3-벤조디아제핀 | |
| US11634412B2 (en) | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | |
| AU9340998A (en) | New epothilone derivatives, method for producing same and their pharmaceutical use | |
| JP5655070B2 (ja) | 新規６，７，８，９−テトラヒドロピリミド｛１，２−ａ｝ピリミジン−４−オン誘導体、これらの調製およびこれらの医薬的使用 | |
| KR20160137635A (ko) | 감마-세크레타제 조절제로서의 크로멘 및 1,1a,2,7b-테트라히드로시클로프로파[c]크로멘 피리도피라진디온 | |
| JP2024520648A (ja) | ナトリウムチャネルの調節因子としての置換テトラヒドロフラン－２－カルボキサミド | |
| EP1761514A1 (en) | Novel tetracyclic tetrahydrofuran derivatives | |
| TW202416949A (zh) | 三環性螺化合物之用途 |